Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older
Completed · Phase 1 · NCT06604767
Conditions: Respiratory Syncytial Virus Infection, Metapneumovirus Infection, Parainfluenzae Virus Infection
At a glance
- Research payments reported, 2025
- $21,000
- U.S. investigators named
- 0
- Sites paid
- 1
- Planned or actual enrollment
- 390
About the trial
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Tested
- parainfluenza virus type 3 vaccine (PIV3) (biological), RSV/hMPV/PIV3 vaccine (biological), RSV/hMPV vaccine (biological), RSV vaccine 1 (biological), RSV vaccine 2 (biological)
- Dates
- Started 2024-09-17; completion 2026-03-24
- Results posted
- Not yet
The purpose of this phase 1 study is to evaluate whether the vaccine is safe and can help the body to develop germ fighting agents called "antibodies" (immunogenicity) against the respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3). The study will use different doses of PIV3 only and different combinations of RSV/hMPV/PIV3 or RSV/hMPV or only RSV vaccine in adults aged 60 years and older.
From ClinicalTrials.gov, last updated 2026-04-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi Pasteur Inc. reported $21,000 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.